Background: There are safety concerns regarding the use of anticholinergics in the COPD patient population. The purpose of this review was to evaluate the cardiovascular risk of regular use of inhaled tiotropium bromide in patients with COPD of any severity. Methods: Systematic searches were conducted in MEDLINE, EMBASE, the Cochrane Controlled Trials Register, manufactures' trial register, and FDA databases, without language restriction. Primary outcomes were a composite of major adverse cardiovascular events, cardiovascular mortality, and nonfatal myocardial infarction (MI) or stroke during the treatment period. Relative risks (RR) were estimated using fixed-effects models and statistical heterogeneity was estimated with the I 2 statistic. Results: Nineteen randomized controlled trials (18,111 participants) were selected. There was no difference in the incidence of adverse cardiovascular events (RR Z 0.96; 95% CI, 0.82e1.12, I 2 Z 6% 
Introduction
Chronic obstructive pulmonary disease (COPD) is a major public health problem.
1,2 Current treatments may reduce symptoms, increase exercise capacity, reduce the number or severity of exacerbations, and improve the health status of patients. Treatment guidelines indicate that bronchodilators are the standard of care in COPD patients. 1, 2 Specifically, anticholinergic agents are of particular value since vagal cholinergic tone appears to be a reversible component of airway narrowing. 3 Tiotropium bromide, the most widely prescribed agent for the treatment of COPD in the world [ 2004 . It is a synthetic quaternary anticholinergic agent with two important characteristics: it acts through prolonged M3 muscarinic receptor antagonism, 4 and has a long duration of action, making it appropriate for once daily therapy. 5, 6 Substantial evidence from controlled studies in patients with COPD has shown greater benefits with tiotropium than with placebo, ipratropium or salmeterol. 7, 8 Although a previous pooled analysis of 19 short-term placebo-controlled trials revealed no significant increase in the risk of cardiovascular (CV) adverse events with tiotropium bromide, 9 two recent publications, a nested caseecontrol study, 10 and a systematic review with metaanalysis 11 reported an increased risk for all-cause and CV mortality, myocardial infarction (MI) and stroke in COPD patients who received tiotropium or inhaled anticholinergics. Nevertheless, these studies have received critics like inability to adjust for the duration of the treatment or double-counting of trials. On the contrary, a recent pool analysis 12 which combines data from the tiotropium trials included in the Singh meta-analysis 11 with published data from the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial 13 concludes that tiotropium does not carry CV risks. However, this analysis did not include information on its methodology, and only assessed composite outcomes. Thus, accounting for these contradictory and limited messages regarding the security of inhaled anticholinergics, we performed an independent systematic review (according to the QUOROM statements 14 
)
to evaluate the safety of regular use of inhaled tiotropium bromide in patients with any severity of COPD.
Methods
Search strategy and eligibility criteria fda.gov) clinical trials databases was performed. Third, reviews and texts were searched for citations. Finally, we contacted the manufacturer of tiotropium and obtained data from an updated integrated tiotropium clinical trial database. Trials published solely in abstract form were excluded because methods and results could not be fully analyzed. The search was without language restriction and unpublished studies were included.
The specific inclusion criteria were: 1) adult patients aged greater than 35 years with stable COPD satisfying American Thoracic Society/European Respiratory Society, or GOLD diagnostic criteria 1,2 ; 2) intervention: inhaled tiotropium bromide as the intervention drug compared with placebo or long-acting beta agonists (LABA) or LABA plus inhaled corticosteroid (ICS); 3) length of treatment: studies with more than 4 weeks of duration; 4) design: randomized (parallel group or cross-over) controlled trials (RCT); 5) primary outcomes: major adverse CV outcome composite (composite of nonfatal MI, stroke and CV death), CV mortality (including sudden death), nonfatal MI, and nonfatal stroke (including transient ischemic attack) during treatment period. All-cause mortality was determined as a secondary outcome.
Data extraction and validity assessment
Titles, abstracts, and citations were independently analyzed by all reviewers. From full text, they independently assessed studies for inclusion based on the criteria for population, intervention, study design and outcomes. Any disagreement over study inclusion was resolved by consensus. Two reviewers (GJR and LJN) extracted data from the selected studies and assessed each study for the sequence generation, allocation sequence concealment, blinding, incomplete outcome data, and selective outcome reporting and other potential sources of bias. 15 In the case of multiple published or unpublished reports for a particular study, data from the most recent version were extracted.
Data analysis
All outcomes were pooled using common relative risk (RR) and 95% confidence interval (CI). If pooled effect estimates for dichotomous outcomes were significantly different between groups, we calculated the number needed to harm (NNH) to cause an event. Heterogeneity was tested by means of the DerSimonian and Laird Q statistic. Heterogeneity was further measured by using the I 2 test. 16 Values of 50% or more indicate a substantial level of heterogeneity. Without substantial heterogeneity, data were combined by mean of a fixed-effects model 17 ; otherwise, a randomeffects model was used. 18 A predefine sensitivity analysis was conducted to explore the influence of the following factors: the effect size for concealment allocation 15 (adequate vs. unclear), trial duration (long-term >6 months to 4 years vs. short-term 6 weeks to 6 months), concomitant use of inhaled corticosteroids (55% of patients vs. <55% of patients) and smoking history (55 pack-years vs. <55 pack-years). Subgroups were compared using the interaction test. 19 A p value < 0.05 using a two-tailed test was considered to indicate significance. This meta-analysis was performed with the Review Manager 5.0.20 (Nordic Cochrane Centre, Copenhagen, Denmark).
Results
A total of 19 RCT including 18,111 patients met the inclusion criteria and were selected for analysis ( Fig. 1 ). Of them, fifteen studies compared tiotropium vs. placebo, 13,23e36 two studies compared tiotropium vs. salmeterol/fluticasone (SF), 20, 37 one study compared tiotropium vs. salmeterol vs. placebo, 22 and one compared tiotropium vs. salmeterol. 21 Two trials were unpublished. 32, 33 There was a total agreement between the reviewers on inclusion of studies. Some of the selected studies reported results for patients enrolled in previous trials. Thus, Casaburi et al. 23 reported combined results from Casaburi et al. 38 and a similar unpublished trial. Likewise, Brusasco et al. 22 presented combined results of Donohue et al. 39 and a similar unpublished trial. Therefore, only Casaburi et al. 23 and Brusasco et al. 22 studies were included in the analysis. There were seven long-term trials 13, 23, 25, 28, 31, 32, 34 (28 weeks to 48 months) and twelve short-term trials 20e22, 24,26,27,29,30,33,35e37 (8 weeks to 6 months) ( Table 1 ). The mean age of patients was 64.8 years (74% of males), with an average baseline FEV 1 of 41% of predicted normal values. Regarding allocation concealment, it was adequate in only 4 studies 13, 30, 34, 37 and unclear in the remaining fifteen. Withdrawal rate was available for all trials and ranged from 0% to 45.1%. The withdrawal rate was lower with tiotropium than with placebo (25.4% vs. 31.1%, p Z 0.0001) or salmeterol (12.4% vs. 16.0%, p Z 0.05). Contrary, the withdrawal rate was significantly higher with tiotropium compared with SF (38.6% vs. 33.0%, p Z 0.03). Tiotropium was administered once a day via a HandiHaler device (Boehringer Ingelheim, Ingelheim am Rhein, Germany, 18 mcg) in 18 studies, and via the Respimat device (Boehringer Ingelheim, Ingelheim am Rhein, Germany, 5 or 10 mcg) in one study. 36 
Primary outcomes
Data from fifteen studies 13,20,22e26,28e32,34,36,37 with 15,695 patients (thirteen comparing tiotropium vs. placebo) showed no significant difference in the incidence of major composite adverse CV events between the tiotropium and control groups (3.6% vs. 4.0% respectively) (Fig. 2) . The post-hoc subgroup analysis (based in thirteen trials that compared tiotropium with placebo) ( Table 2 ) did not show significant differences regarding the duration of treatment, allocation concealment, and concomitant use of ICS. On the contrary, studies with COPD patients with a smoking history 55 pack-years presented a trend to a higher rate of composite CV events. It is to emphasize that the analysis of the two studies 20, 37 that compared tiotropium with SF showed an opposite effect with a significant higher incidence of adverse events in the tiotropium group.
Among individual components of the composite outcome, ten studies 13, 22, 23 ,29e32,34,36,37 involving 13,356 patients (nine studies comparing tiotropium vs. placebo) showed that inhaled tiotropium did not significantly increase the risk of CV death (1.7% vs. 1.9% respectively) Figure 1 Flowchart for identification of usable studies. (Fig. 3) . On the other hand, inhaled tiotropium did not significantly increase the risk of nonfatal MI compared with placebo, or salmeterol or SF (1.6% vs. 2.0% respectively) (Fig. 4) . Finally, the incidence of nonfatal stroke was equivalent with tiotropium than with controls (1.8% vs. 1.8% respectively) (Fig. 5) . There was no evidence of statistical heterogeneity among the included trials for any of these end points. Because one study 13 contributed with the largest weight in the fixed-effects model, we excluded it in a new analysis limited to the remained trials. However, this exclusion did not change the primary conclusions on adverse CV composite (RR Z 1.31; 95% CI, 0.94e1.81, I 2 Z 0%, p Z 0.57), CV mortality (RR Z 1.68; 95% CI, 0.98e2.78; I 2 Z 0%, p Z 0.08), MI (RR Z 0.94; 95% CI, 0.59e1.52; I 2 Z 0%, p Z 0.81), and stroke (RR Z 1.12; 95% CI, 0.43e2.90; I 2 Z 0%, p Z 0.81) respectively.
Secondary outcome
Tiotropium did not significantly increase the risk of allcause mortality (RR Z 0.97; 95% CI, 0.86e1.09; I 2 Z 20%, p Z 0.61) in meta-analysis of sixteen studies 13,21e25,27,29e37 involving 17,051 patients. Once more, a study comparing tiotropium with SF 37 showed a significant higher incidence of all-cause deaths in the tiotropium group (RR Z 1.87; 95% CI, 1.07e3.28, p Z 0.03). Finally, the exclusion of the study by Tashkin et al. 13 did not modify the conclusion (RR Z 1.15; 95% CI, 0.85e1.57; I 2 Z 18%, p Z 0.33).
Discussion
This is the largest systematic review with meta-analysis designed to evaluate the safety of regular use of tiotropium bromide in patients with COPD of any severity. Our analysis included 19 RCT (comparing tiotropium with placebo, or with salmeterol or with SF), with more than 18,000 patients, and found that tiotropium did not increase the risk of CV mortality, nonfatal CV events (MI and stroke), and all-cause mortality compared with controls. However, because most of included studies compared tiotropium with placebo, these conclusions are based mainly in this comparison. However, when we included in the analysis data from four studies 20e22,37 that compare tiotropium with salmeterol or SF, the summary effect estimate did not change, without evidence of clinical and statistical heterogeneity between trials. A more detailed analysis showed that contrary to the tiotropium vs. salmeterol comparisons that presented similar conclusions to tiotropium vs. placebo comparisons, tiotropium vs. SF comparisons 20, 37 displayed an opposite tendency. Thus, the use of SF was associated with a non-significant lower incidence in CV mortality 37 and MI incidence. 20e37 In a similar way, the Wedzicha et al. trial 37 showed a significant decrease in the all-cause mortality rate compared with tiotropium, suggesting a protective effect of ICS. Although the withdrawal rate was similar between tiotropium and SF in a 6-week trial, 20 in the 2-year Wedzicha study 37 the withdrawal rate was significantly higher with tiotropium compared with SF (due to COPD exacerbations, perceived lack of efficacy, or unwillingness to remain in the study). Conversely, there was a small but significant increase in reported pneumonia in the SF-treated group.
The influence on the results was explored through sensitivity analysis (Table 2) . Although limited by its posthoc nature, the subgroup analysis suggests that some factors could modify the risk of CV adverse events. Thus, while there were no significant differences between short and long-term trials, adequate or unclear allocation concealment, and concomitant use of ICS, data suggested that the risk could be modified according the CV risk profile of patients. Thus, patients with a smoking history of 55 pack-years presented a trend to a higher incidence of major CV adverse events. The results of our review contradict a recent metaanalysis that focused on the CV safety of anticholinergics in COPD. Specifically, Singh et al. 11 performed a systematic review on the basis of 17 selected RCT, and concluded that anticholinergics (tiotropium and ipratropium) are associated with a significantly increased risk of CV death, MI or stroke. However, there were several important differences between the Singh et al. study and our current analysis. 1) Singh et al. 11 performed a pool analysis of a mix of studies that compared tiotropium vs. placebo (eight studies), tiotropium vs. salmeterol (one study), tiotropium vs. SF (one study), tiotropium vs. salmeterol vs. placebo (two studies), ipratropium vs. placebo (one study), ipratropium vs. salmeterol (one study), and ipratropium vs. albuterol vs. placebo (three studies). So, placebo-controlled trials were pooled together with active controlled trials, assuming that the comparator drug is interchangeable with a placebo. 2) On the contrary, we focus our analysis exclusively to tiotropium comparisons (vs. placebo, salmeterol or SF).
3) The meta-analysis by Singh et al. showed a significant increase in the nonfatal or fatal cardiovascular risk based in the ipratropium vs. control comparison (RR Z 1.70; 95% CI, 1.19e2.42, I
2 Z 0%, p Z 0.003). Contrary, in the same analysis, twelve studies that compared tiotropium vs. control (placebo or salmeterol or SF) did not show a significant higher incidence of adverse severe cardiovascular events (RR Z 1.43; 95% CI, 0.95e2.16; p Z 0.08; I 2 Z 0%, p Z 0.08). The difference in the CV events was primary derived from four (three comparing tiotropium with placebo 23,25e31 and one with SF 37 ) long-term studies (duration of study > 6 months). Furthermore, the difference in CV events could be due to bias. Thus, Oba et al. 12 found evidence of possible publication bias when long-term studies were analyzed statistically and graphically. 4) Two of the twelve included studies 38, 39 presented redundant data and should have been excluded. 5) Our review added 9 new RCT studies 13,21,24,27,28,32e35 with more than 10,000 patients. 6) The Singh et al. study 11 assessed as a primary outcome measure a composite of nonfatal major adverse CV events and CV death; additionally, the risk of all-cause mortality was determined as a secondary outcome. Our review not only includes these two outcomes but also adds to the analysis the incidence of MI, stroke and CV deaths. 7) In the Singh et al. review, the number of the control group in the study by Chan et al. 25 was 305 instead 350. Our review meets most of the methodological criteria suggested for scientific reviews. 14 We selected seven new published and two unpublished RCT that reported at least one fatal or nonfatal CV event, with more than 10,000 new COPD patients; additionally, we excluded two redundant studies 33, 34 selected in a previous review. 11 All of the selected studies were RCT and combined with no evidence of clinical and statistical heterogeneity between trials, increasing the confidence of our findings. Among the studies added, the UPLIFT trial 13 is the longest (4-year) and largest study (almost 6000 patients with COPD) that compared inhaled tiotropium with placebo. However, the UPLIFT study is different from previous tiotropium trials. Thus, because its protocol allowed the use of short acting anticholinergics for the treatment of COPD exacerbations, the potential cardiotoxic effect of these drugs administered in both arms, could potentially mask the CV adverse effects of tiotropium. However, after we excluded this study, the conclusions did not change through the different outcomes assessed.
There are some potential limitations that come from the fact that none of these trials were specifically designed to monitor CV events, therefore, the reporting of CV outcomes may have been incomplete. Also, the fact that most of included studies reported adverse effects only during the treatment period could increase the probability of bias. Finally, the fact that 80% of the reviewed patients were men limits the applicability of results since COPD is suspected to affect men and women equally.
In summary, the conclusions of this review were: 1) inhaled tiotropium did not increase the risk of major adverse CV events (MI, stroke, CV deaths) and all-cause mortality. 2) Unlike other comparisons (tiotropium vs. placebo or salmeterol), the use of SF was associated with a lower incidence in CV events and all-cause mortality compared with tiotropium, suggesting a protective effect of ICS. Conversely, there was a small but significant increase in reported pneumonia in the SF-treated group. Nevertheless, these conclusions are based mainly in data from one study. 3) Subgroup analysis suggests that the smoking history could modify the risk of CV adverse events. So, caution should be advised in patients at risk for CV disease. The same is true for SF in patients at high risk for pneumonia. 4) Because none of the trials were prospectively designed to assess the CV risk of inhaled anticholinergics in patients with COPD, CV outcomes may not have been prospectively defined in a uniform fashion across the trials. Adequately designed randomized trials prespecified on CV outcomes will allow to clarify completely this issue.
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